Aug. 20 was a day of vindication for Amicus Therapeutics Inc., which now has positive Phase III results on its oral Fabry disease therapy migalastat and a comprehensive data package to submit to FDA – two years after the first portion of a Phase III trial disappointed and a year after the rare disease drug developer lost its big pharma partner.
Migalastat could become the first oral small molecule treatment for a portion of patients with the rare inherited disease, who are currently treated with enzyme replacement therapies that require infusions every
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?